PT  - JOURNAL ARTICLE
AU  - Çelik, Senol
AU  - Ankarali, Handan
AU  - Pasin, Ozge
TI  - MODELLING OF COVID-19 OUTBREAK INDICATORS IN CHINA BETWEEN JANUARY AND APRIL
AID  - 10.1101/2020.04.26.20080465
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.26.20080465
4099  - http://medrxiv.org/content/early/2020/05/01/2020.04.26.20080465.short
4100  - http://medrxiv.org/content/early/2020/05/01/2020.04.26.20080465.full
AB  - Background The aim of this study is to explain the changes of outbreak indicators for coronavirus in China with nonlinear models and time series analysis. There are lots of methods for modelling. But we want to determine the best mathematical model and the best time series method among other models.Methods The data was obtained between January 22 and April 21, 2020 from China records. The number of total cases and the number of total deaths were used for the calculations. For modelling Weibull, Negative Exponential, Von Bertalanffy, Janoscheck, Lundqvist-Korf and Sloboda models were used and AR, MA, ARMA, Holt, Brown and Damped models were used for time series. The determination coefficient (R2), Pseudo R2 and mean square error were used for nonlinear modelling as criteria for determining the model that best describes the number of cases, the number of total deaths and BIC (Bayesian Information Criteria) was used for time series.Results According to our results, the Sloboda model among the growth curves and ARIMA (0,2,1) model among the times series models were most suitable models for modelling of the number of total cases. In addition Lundqvist-Korf model among the growth curves and Holt linear trend exponential smoothing model among the times series models were most suitable model for modelling of the number of total deaths. Our time series models forecast that the number of total cases will 83311 on 5 May and the number of total deaths will be 5273.Conclusions Because results of the modelling has providing information on measures to be taken and giving prior information for subsequent similar situations, it is of great importance modeling outbreak indicators for each country separately.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding in the study.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yeshttps://www.who.int/news-room/detail/08-04-2020-who-timeline---covid-19